European Federation of Pharmaceutical Industries and Associations (EFPIA)

Warning! LobbyFacts is temporarily only showing data up to 19 September 2021. This is because from 20 September, the EU lobby register changed format and the register's secretariat is no longer providing complete and reliable daily data updates which LobbyFacts uses to keep up to date. This temporary problem has not affected LobbyFacts' archive facility, but for today's lobby data, please check the original EU lobby register. We hope the secretariat will remedy this soon, enabling us to launch a new improved and faster version of LobbyFacts.

Tweet this page
How to read and use this data card.

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

5,250,000€ - 5,499,999€

Financial year: 01/01/2020 - 01/12/2020

Lobbyists declared: 9 FTE (25)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.


Lobbyists with EP accreditation: 10


Meetings with European Commission: 103

Lobbying costs over the years:


European Federation of Pharmaceutical Industries and Associations (EFPIA)

Registration on EU Transparency Register

38526121292-88 (First registered: 04 Mar 2009)

Goals / Remit

EFPIA represents the biopharmaceutical industry operating in Europe. Through its direct membership of 36 national associations, 39 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and
better outcomes for patients.

EFPIA’s activities extend to all matters of common interest to its members. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.


Any health or pharmaceutical policy stemming from the European institutions, such as life sciences strategy, industrial policy, European Semester, Horizon Europe Research Programme, HTA policy, IP policy, Pharmaceutical Strategy, One Health Approach to tackle AMR, pharmaceutical, orphan and paediatrics legislation, COVID-19 outbreak measures. EFPIA also follows ongoing trade negotiations and legislative files when relevant to the innovative pharmaceutical industry (such as Green Deal, Water Framework Directive, Welfare of animals in scientific testing etc).


Head office:
8 Rue Mil Neuf Cents
Luxembourg L-2157

Tel: 32 26262555

Belgium office:
Rue du Trône 108
Brussels 1050,

Tel: 32 26262555